INVEGA® Receives European Commission Approval To Extend Its Adult Indication For Treatment Of Schizophrenia To Include Adolescents Aged 15 Years And Older

Janssen-Cilag International NV announced that the European Commission has approved an extension of the oral atypical antipsychotic Invega (paliperidone ER) schizophrenia indication, to include adolescents aged 15 years and older. The decision from the European Commission follows a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency in April 2014.

"This decision means that Invega becomes an additional treatment choice available to physicians and to young people living with schizophrenia," said Andreas Schreiner, European Therapy Area Lead, Neuroscience and Pain. "We are therefore delighted that the European Commission has approved Invega for . . .